Literature DB >> 11850011

Resistance and susceptibility in human onchocerciasis--beyond Th1 vs. Th2.

Achim Hoerauf1, Norbert Brattig.   

Abstract

As research progress has led to programs for the elimination of onchocerciasis as a public health problem, research must now be intensified to protect elimination efforts. A profound understanding of the immunology in the human-parasite relationship is required for predicting the impacts of an altered immune response in a population post-microfilaricide treatment, and for the development of a vaccine against onchocerciasis, a highly desirable tool to guarantee sustained elimination success. This article summarizes the recent advancements in understanding the human immune mechanisms against onchocerciasis, and focuses on the new concept of T-cell suppressor responses as a major counterbalance mechanism for effector responses driven by T helper 1 and T helper 2 cells against the filarial worms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850011     DOI: 10.1016/s1471-4922(01)02173-0

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  34 in total

1.  Identifying sub-optimal responses to ivermectin in the treatment of River Blindness.

Authors:  Thomas S Churcher; Sébastien D S Pion; Mike Y Osei-Atweneboana; Roger K Prichard; Kwablah Awadzi; Michel Boussinesq; Richard C Collins; James A Whitworth; María-Gloria Basáñez
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-17       Impact factor: 11.205

2.  Protective immunity to the larval stages of onchocerca volvulus is dependent on Toll-like receptor 4.

Authors:  Laura A Kerepesi; Ofra Leon; Sarah Lustigman; David Abraham
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 3.  Onchocerca volvulus: The Road from Basic Biology to a Vaccine.

Authors:  Sara Lustigman; Benjamin L Makepeace; Thomas R Klei; Simon A Babayan; Peter Hotez; David Abraham; Maria Elena Bottazzi
Journal:  Trends Parasitol       Date:  2017-09-22

4.  Differential induction of Th2- and Th1-associated responses by filarial antigens and endosymbiotic Wolbachia in a murine model of river blindness.

Authors:  K Gentil; A Hoerauf; E Pearlman
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2012-06-13

5.  Interleukin-10 (IL-10) counterregulates IL-4-dependent effector mechanisms in Murine Filariasis.

Authors:  Sabine Specht; Lars Volkmann; Tom Wynn; Achim Hoerauf
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

Review 6.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

7.  Immunohistology of ectopic secondary lymph follicles in subcutaneous nodules from patients with hyperreactive onchocerciasis (sowda).

Authors:  Norbert W Brattig; Klara Tenner-Racz; Simone Korten; Achim Hoerauf; Dietrich W Büttner
Journal:  Parasitol Res       Date:  2010-06-04       Impact factor: 2.289

8.  Synergism of gamma interferon and interleukin-5 in the control of murine filariasis.

Authors:  Michael Saeftel; Manuela Arndt; Sabine Specht; Lars Volkmann; Achim Hoerauf
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  Resistance and susceptibility to filarial infection with Litomosoides sigmodontis are associated with early differences in parasite development and in localized immune reactions.

Authors:  Simon Babayan; Marie-Noëlle Ungeheuer; Coralie Martin; Tarik Attout; Elodie Belnoue; Georges Snounou; Laurent Rénia; Masataka Korenaga; Odile Bain
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

10.  Lymphatic vascularisation and involvement of Lyve-1+ macrophages in the human onchocerca nodule.

Authors:  Tarik Attout; Achim Hoerauf; Gaëlle Dénécé; Alexander Yaw Debrah; Yeboah Marfo-Debrekyei; Michel Boussinesq; Samuel Wanji; Valérie Martinez; Sabine Mand; Ohene Adjei; Odile Bain; Sabine Specht; Coralie Martin
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.